A world in which a simple blood draw will be sufficient to perform a cancer diagnosis and monitoring, enabling physicians to select the best treatment for each patient.
Caring with Honesty – High Standards – Making a Difference Through Innovative Thinking – Teamwork – Partnership and Trust
We provide true tumor biopsy in a routine blood sample, truly suitable for low interval screening and for active surveillance and monitoring.
We rely on a unique biological principle and evolving science to build and fully validate highly sensitive and specific diagnostic tests.
Our approach is based on fundamental drivers of cancer (e.g. metabolic switch) and exosomes as early sentinels of tumor growth.
Our tests are simple, reliable, and cost-effective; we offer scalable and familiar test formats and provide them as an open platform tools .
Current investors are: Lonza, BioBalt Holding, BioFund, FinBiotech Srl, and Black Swan Trade Ltd.